Merck & Co., Inc.
MRK
$120.87
+0.02%
Merck & Co., Inc. is a global pharmaceutical company operating in the Drug Manufacturers - General industry. It is a leading player defined by its dominant immuno-oncology platform, led by Keytruda, and a substantial vaccine business including Gardasil.
MRK
Merck & Co., Inc.
$120.87
Related headlines
Investment Opinion: Should I buy MRK Today?
Based on a synthesis of strong fundamentals, strategic positioning, and balanced risks, the objective assessment points to a Hold rating. The company's quality is undeniable, with superb profitability and a market-leading product. However, the stock's recent sharp appreciation to near all-time highs, coupled with the long-term patent cliff overhang, suggests limited near-term upside and increased vulnerability to any missteps in its growth transition. New money may find better entry points on market pullbacks.
Sign up to view all
MRK 12-Month Price Forecast
The analysis indicates a high-quality company at a fair-to-full valuation. The near-term path is likely one of consolidation (base case) as the market awaits clearer signs of post-Keytruda growth. The low probability assigned to the bear case reflects the company's financial resilience.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co., Inc.'s 12-month outlook, with a consensus price target around $157.13 and implied upside of +30.0% versus the current price.
Average Target
$157.13
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$97 - $157
Analyst target range
Wall Street analyst coverage for Merck is active, with recent ratings from major firms including 'Outperform' from RBC Capital and Wells Fargo, 'Buy' from Guggenheim, and 'Neutral' or 'Hold' from Citigroup, TD Cowen, and others. The consensus among nine analysts points to an estimated average EPS of $10.16 for the upcoming period, with revenue estimates averaging $74.14 billion. Specific consensus target price data is not available in the provided inputs.
Bulls vs Bears: MRK Investment Factors
Merck presents a compelling mix of current strength and future uncertainty. Its dominant market position, exceptional profitability, and strategic initiatives are clear positives. However, the stock's significant run-up and the overarching threat of its key drug's patent expiration create a balanced risk-reward profile for the near to medium term.
Bullish
- Dominant Immuno-Oncology Platform: Keytruda is a leading drug with strong sales, driving revenue and profitability.
- Exceptional Financial Health: Robust ROE of 34.7%, strong free cash flow of $12.36B, and solid liquidity.
- Strong Market Outperformance: Stock up 34.4% over 6 months, significantly beating the S&P 500.
- Active Pipeline & Strategic M&A: 80 Phase 3 studies and recent acquisitions aim to address patent cliff.
Bearish
- Looming Keytruda Patent Cliff: Major revenue source faces future patent expiration, creating significant uncertainty.
- Premium Valuation After Rally: Stock trades at 96% of 52-week high; PEG ratio of 1.88 suggests full valuation.
- Moderate Revenue Growth: Recent quarterly revenue growth of 5% is solid but not explosive.
- Acquisition Execution Risk: Large deals like Terns Pharma carry integration and overpayment risks.
MRK Technical Analysis
Overall Assessment: The stock has demonstrated a strong uptrend over the past six months, with a price increase of 34.39% from $89.51 on October 2, 2025, to $120.29 on March 31, 2026. This performance significantly outpaces the broader market, as evidenced by a 37.21% six-month relative strength versus the S&P 500.
Short-term Performance: Over the last three months, the stock gained 14.28%, again strongly outperforming the S&P 500, which fell 4.63%. However, the stock experienced a pullback of 2.85% over the past month, though this still represents outperformance against the S&P 500's 5.25% decline.
Current Position: The current price of $120.29 is near the upper end of its 52-week range of $73.31 to $125.14, trading approximately 96% of the way toward its 52-week high. The stock's beta of 0.264 indicates it has been significantly less volatile than the market during this period.
Beta
0.26
0.26x market volatility
Max Drawdown
-22.9%
Largest decline past year
52-Week Range
$73-$125
Price range past year
Annual Return
+39.6%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | +0.9% | -3.6% |
| 3m | +13.5% | -4.0% |
| 6m | +35.5% | -2.0% |
| 1y | +39.6% | +16.2% |
| ytd | +13.5% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Revenue & Profitability: The company's most recent quarterly revenue (Q4 2025) was $16.4 billion, representing a year-over-year growth of 4.97%. Profitability remains robust with a net margin of 18.07% for the quarter, supported by a high gross margin of 92.71% and an operating margin of 53.27%.
Financial Health: The company maintains a solid current ratio of 1.54, indicating good short-term liquidity. The debt-to-equity ratio stands at 0.96, reflecting a moderate level of leverage. Cash flow generation is strong, with trailing twelve-month free cash flow reported at $12.36 billion.
Operational Efficiency: Return on Equity (ROE) is exceptionally high at 34.70%, indicating efficient use of shareholder capital. Return on Assets (ROA) is also healthy at 12.04%. The company's asset turnover, while not provided in the latest key metrics, has historically been in line with industry norms for a capital-intensive pharmaceutical firm.
Quarterly Revenue
$16.4B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.92%
Latest Quarter
Free Cash Flow
$12.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
Valuation Level: Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 14.46, while the forward P/E is 12.32, based on estimated EPS of $10.16. The PEG ratio is 1.88, suggesting the stock may be fairly valued relative to its earnings growth expectations.
Peer Comparison: Data not available for direct industry average comparisons from the provided inputs. However, the company's EV/EBITDA of 11.83 and Price/Sales ratio of 4.06 provide additional context for its valuation relative to its own sales and cash flow generation.
PE
14.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -57x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.8x
Enterprise Value Multiple
Investment Risk Disclosure
Merck's primary risk is the impending patent expiration of its blockbuster drug Keytruda, which contributes a substantial portion of revenue. The company's strategic response, including the $6+ billion acquisition of Terns Pharmaceuticals and a pipeline of 80 Phase 3 studies, carries inherent execution and integration risks. If new products fail to gain traction or acquisitions underperform, future growth could stall.
Financial risks are moderate. The company carries a debt-to-equity ratio of 0.96, which is manageable given its strong cash flow generation of $12.36 billion TTM. However, trading near its 52-week high (96% of the high) after a 34% six-month rally introduces valuation risk, especially if market sentiment sours or growth estimates are revised downward. The stock's low beta of 0.26 suggests it is less volatile than the market, but this does not eliminate fundamental business risks.
External risks include intense competition in oncology and vaccine markets, potential regulatory setbacks for pipeline drugs, and the possibility that rival bids could inflate the price of acquisition targets like Terns. The company's heavy reliance on the US market (47% of sales) also exposes it to region-specific healthcare policy changes.
FAQ
The paramount risk is the patent expiration of Keytruda, its largest revenue driver, which creates a future earnings cliff. Execution risk on new acquisitions (like Terns Pharma) and its pipeline of 80 Phase 3 studies is significant. Additionally, the stock's premium price after a 34% rally introduces valuation risk, and the company's moderate debt level (D/E of 0.96) requires careful management.
The 12-month outlook is for consolidation with a neutral bias. The base case (55% probability) sees a trading range of $115-$128, aligning with steady execution of its $10.16 EPS estimate. The bull case (30%) could see a breakout to $130+ on successful pipeline news, while the bear case (15%) could see a pullback toward $95-$110 if patent concerns intensify or the market corrects.
MRK appears fairly valued to slightly fully valued. Its forward P/E of 12.3x is reasonable for a stable pharmaceutical giant, and its PEG ratio of 1.88 suggests the market is pricing in its growth prospects. However, trading near the top of its 52-week range after a major rally limits the margin of safety. It is not dramatically overvalued, but it is also not clearly undervalued.
Based on current data, MRK is a Hold, not a strong Buy. The company is exceptionally profitable with an ROE of 34.7% and strong cash flow. However, the stock has risen 34% in six months and trades at 96% of its 52-week high, embedding much of the near-term optimism. The looming Keytruda patent expiration also creates a long-term overhang that tempers the buying case at these levels.
MRK is more suitable for a long-term, income-oriented investor who can tolerate the multi-year transition away from Keytruda. Its 3.1% dividend yield and strong cash flow provide downside support. The short-term outlook is clouded by valuation after the rally and event-driven news on M&A and pipeline data, making it less ideal for short-term trading focused on quick gains.